Observational studyAdvances in therapy2025
Risk Factors Associated with Suboptimal Real-World Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Treated with Front-Line Recommended Therapy.
Observational study in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Second-Line Therapy Following Osimertinib in Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer at an Academic Medical Center.Cancer reports (Hoboken, N.J.) · 2026Article
- Prognostic factors of epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitor (TKI): a nationwide registry study in China.Translational lung cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOsimertinib, a recommended front-line (1L) treatment option for non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations [exon 19 deletion (ex19del)/exon 21 L858R substitution (L858R)], demonstrated significantly improved progression-free survival and overall survival (OS) compared with other EGFR tyrosine kinase inhibitors in the FLAURA trial. However, most patients developed secondary resistance, and subpopulations experienced disparate outcomes. This retrospective, observational study aimed to describe real-world treatment outcomes along with patient clinical characteristics associated with different clinical outcomes among patients with EGFR-mutated (ex19del/L858R) NSCLC who received osimertinib as 1L therapy.
methodsThis retrospective cohort study of patient clinical and genomic data from a de-identified, US-based, nationwide NSCLC clinico-genomic database evaluated OS, time-to-next-treatment (TTNT), and time-to-discontinuation (TTD) among patients with EGFR-mutated NSCLC who received 1L osimertinib monotherapy and identified patient characteristics associated with differences in clinical outcomes as related to real-world 1L osimertinib use.
resultsAmong 703 identified patients, mean age was 69 years, 67% of patients were female, and 53% were White. Median OS was 29.8 months, TTNT was 17.6 months, and TTD was 15.9 months. A large majority of the overall population had risk factors associated with suboptimal real-world outcomes (97% for OS, 95% for TTNT, and 87% for TTD), even among patients with ECOG PS scores of 0-1. Key individual risk factors identified included metastases of the liver, bone, and central nervous system; ECOG PS scores ≥ 2; and TP53, CDK-4, and EGFR L858R mutations.
conclusionsMore than 90% of the assessed real-world patients with EGFR-mutated (ex19del/L858R) NSCLC who received 1L osimertinib had risk factors associated with suboptimal outcomes, highlighting the urgent unmet need for new treatments and emphasizing the importance of administering the most effective therapy in the 1L setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.